CSO Lindsay Davies Co-Chairs ISCT Europe 2024 Meeting

September 3, 2024

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), a leader in advanced cell therapy and immunotherapy research, is proud to announce that Dr. Lindsay Davies, the company’s Chief Scientific Officer (CSO) and ISCT Europe Regional Secretary, serves as Co-Chair together with Dr. Massimiliano Gnecchi of the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting, held in Gothenburg, Sweden, from September 4-6.

"We are thrilled to have Dr. Davies representing NextCell Pharma at such an influential event," says Mathias Svahn, CEO of NextCell Pharma AB. "Her expertise in cell therapy and her leadership within ISCT underscore our company's commitment to advancing the science and therapeutic potential of cell-based treatments. This meeting is a great opportunity to showcase the progress NextCell is making in the field of advanced therapies, in particular the 5-year efficacy data with a single infusion of ProTrans for treatment of type-1 diabetes."

The ISCT Europe 2024 Regional Meeting brings together leading researchers, clinicians, and industry professionals from around the world to discuss the latest advances and challenges in the field of cell and gene therapy. This prestigious event focuses on cutting-edge scientific breakthroughs, regulatory trends, and innovative approaches to translating research into clinical applications, aiming to accelerate the development of new therapies for patients.

Dr. Lindsay Davies, in her dual role as CSO of NextCell Pharma AB and ISCT Europe Regional Secretary, has played a pivotal role in organizing the event and will be involved heavily with and steering the discussions during the event. Her leadership has been instrumental in shaping the program, which features high-profile speakers and interactive sessions addressing the most pressing issues in the rapidly evolving field of regenerative medicine.

The ISCT Europe 2024 Regional Meeting covers a wide range of topics, including innovations in stem cell therapies, gene editing technologies, regulatory hurdles, and strategies for commercialization. The event provides a platform for collaboration among industry leaders, academic institutions, and regulatory bodies to further the development of next-generation therapies aimed at treating chronic diseases and those indications with unmet medical needs.

NextCell Pharma AB continues to be at the forefront of cell therapy development with its lead product candidate ProTrans, a mesenchymal stromal cell-based therapy designed to treat autoimmune diseases such as type 1 diabetes. The company remains dedicated to pushing the boundaries of regenerative medicine through scientific innovation, clinical research, and partnerships with leading organizations in the biotech sector.

About ISCT

The International Society for Cell and Gene Therapy (ISCT) is a global association with a focus on driving the translation of scientific research into clinical applications of cell and gene therapies. With over 1,700 members in 50+ countries, ISCT connects academic, regulatory, and commercial stakeholders to advance the field of regenerative medicine.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma


For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se


Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for COVID-19, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.

Download attachmentRead full press release on Cision (external link)
2021-12-13
NextCell collaborates with T.A.D.1 and T1D app
NextCell Pharma AB ("NextCell" or the"Company") has entered into a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D.  Together, we want to spread hope for type 1 diabetes and make NextCell's clinical trials visible. Every year, more than 900 children are diagnosed with type 1 diabetes and at least as many are diagnosed in adulthood. The disease has a huge impact on life and something that needs to be dealt with daily, for the rest of your life.
NextCell Pharma AB ("NextCell" or the"Company") has entered into a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D.  Together, we want to spread h...
Read moreRead more
2021-10-29
NextCell publishes its Year-End Report 2020/2021
NextCell Pharma AB (publ) (NXTCL) publishes its Year-End Report for the period September 1, 2020 - August 31, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. Fourth quarter (2021-06-01 until 2021-08-31) ● Operating income amounted to TSEK 1 381 (842). ● Operating result amounted to TSEK -4 475 (-4 877). ● Earnings per share* amounted to SEK -0,13 (-0,22).
NextCell Pharma AB (publ) (NXTCL) publishes its Year-End Report for the period September 1, 2020 - August 31, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under th...
Read moreRead more
2021-10-26
NextCell to begin treatment with medium dose in COVID-19
NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans19+SE can commence to enroll patients in the medium dose group. Three patients having received a low dose ProTrans, have been clinically assessed and evaluated by the Data and Safety Monitoring Board, which now allows continuation with medium dose treatment of ProTrans for COVID-19 induced servere pneumonia. The Data and Safety Monitoring Board (DSMB) has reviewed safety aspects of the study "Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton's Jelly (WJ) Umbilical
NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans19+SE can commence to enroll patients in the medium dose group. Three patients having received a low dose ProTrans, have been clinically assessed and evaluated by the Data and Safety Monitoring Board, which...
Read moreRead more
2021-10-26
NextCell increases market potential and reduces the risk of ProTrans' clinical trial program in type 1 diabetes
NextCell Pharma AB ("NextCell" or the "Company") updates the strategy for the clinical trial program in type 1 diabetes with ProTrans. The aim is to increase potential while reducing the risk. This can be achieved by waiting for preliminary safetydata from the approved ProTrans-Young pediatric trial before submitting the application for ProTrans-3, scheduled for H2 2022. Advantages of the updated strategy for future application for marketing approval are: · Lower age limit for treatment is desirable and could potentially double the intitial market · Increased long term data from
NextCell Pharma AB ("NextCell" or the "Company") updates the strategy for the clinical trial program in type 1 diabetes with ProTrans. The aim is to increase potential while reducing the risk. This can be achieved by waiting for preliminary safetydata from the approved ProTrans-Young pediatric tr...
Read moreRead more
2021-10-06
NextCell invited speaker at the Advanced Therapy Congress in London
Today, NextCell Pharma AB’s CEO, Dr. Mathias Svahn, is presenting clinical data from the ProTrans-1 and ProTrans-2 diabetes studies. Ranked as one of Europe's most important events in the field of advanced therapies, the ExCel event brings together leading players in the pharmaceutical industry to provide information on the latest technologies attracting more than 2,000 visitors. The scope of the summit is to explore, define and tackle the challenges of, and patient access to ATMPs (Advanced Therapy Medicinal Products), as the field moves into an exciting 2022. NextCell has developed an
Today, NextCell Pharma AB’s CEO, Dr. Mathias Svahn, is presenting clinical data from the ProTrans-1 and ProTrans-2 diabetes studies. Ranked as one of Europe's most important events in the field of advanced therapies, the ExCel event brings together leading players in the pharmaceutical industry t...
Read moreRead more
2021-09-09
All patients in the low-dose group treated with ProTrans
NextCell Pharma AB ("NextCell" or the "Company") announces that three patients with Covid-19 have now been treated with ProTrans in the Swedish study ProTrans19+SE conducted at Örebro University Hospital. As a result, all patients in the low-dose cohort are now treated. The full title of the study is: "Treatment of Respiratory Complications Associated with COVID-19 Infection with Wharton's Jelly (WJ) -Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): An Open Phase IB Clinical Trial", (EudraCT 2020-002078-29). NextCell sponsors the study, which will include a total of nine patients
NextCell Pharma AB ("NextCell" or the "Company") announces that three patients with Covid-19 have now been treated with ProTrans in the Swedish study ProTrans19+SE conducted at Örebro University Hospital. As a result, all patients in the low-dose cohort are now treated. The full title of the stu...
Read moreRead more
2021-08-17
NextCell files patent application for treatment of COVID-19 with ProTrans
NextCell Pharma AB ("NextCell" or the "Company”) announces that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans. NextCell increases the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammatory conditions. The latest patent application has is entitled; "Allogeneic Composition for Treatment off Covid-19". By using the possibility of priority from a previous application, the COVID-19 application has a priori day of August 14, 2020, i.e. dated 1 year back in time. NextCell has filed a
NextCell Pharma AB ("NextCell" or the "Company”) announces that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans. NextCell increases the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammat...
Read moreRead more
2021-07-30
NextCell Pharma publishes Interim Report 3 2020/2021
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2020 - February 28, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. Third quarter (2020-03-01 until 2021-05-31) · Operating income amounted to SEK 905 750 (750 512). · Operating result amounted to SEK -6 457 514 (-4 833 332). · Earnings
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2020 - February 28, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth ...
Read moreRead more